The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125617432 12561743 2 F 20160708 20160715 20160729 EXP CA-HQ SPECIALTY-CA-2016INT000540 INTERCHEM POPADIUK C, POWER P.. PEGYLATED LIPOSOMAL DOXORUBICIN IS AN ACTIVE AGENT FORM CHEMOTHERAPY-RESISTANT CHORIOCARCINOMA: A REPORT OF TWO CASES. JOURNAL OF REPRODUCTIVE MEDICINE. 2016;61(5-6):215-8 33.00 YR F Y 0.00000 20160729 OT CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125617432 12561743 1 PS METHOTREXATE SODIUM. METHOTREXATE SODIUM 1 Unknown CYCLIC Y 201749
125617432 12561743 2 SS CISPLATIN. CISPLATIN 1 UNK Y 0
125617432 12561743 3 SS TAXOL PACLITAXEL 1 Unknown UNK Y 0
125617432 12561743 4 SS ETOPOSIDE. ETOPOSIDE 1 Unknown CYCLIC Y 0
125617432 12561743 5 SS VINCRISTINE SULFATE. VINCRISTINE SULFATE 1 CYCLIC Y 0
125617432 12561743 6 SS GEMCITABINE HYDROCHLORIDE. GEMCITABINE HYDROCHLORIDE 1 UNK Y 0
125617432 12561743 7 SS ACTINOMYCIN D DACTINOMYCIN 1 UNK Y 0
125617432 12561743 8 SS CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE 1 UNK Y 0
125617432 12561743 9 SS PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE DOXORUBICIN HYDROCHLORIDE 1 CYCLIC (35 MG/M2, 1 IN 4 W) Y 0 35 MG/M**2
125617432 12561743 10 C DOXORUBICIN DOXORUBICIN 1 UNK U 0
125617432 12561743 11 C TAXOTERE DOCETAXEL 1 UNK U 0
125617432 12561743 12 C HERCEPTIN TRASTUZUMAB 1 UNK U 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125617432 12561743 1 Choriocarcinoma
125617432 12561743 2 Choriocarcinoma
125617432 12561743 3 Choriocarcinoma
125617432 12561743 4 Choriocarcinoma
125617432 12561743 5 Choriocarcinoma
125617432 12561743 6 Choriocarcinoma
125617432 12561743 7 Choriocarcinoma
125617432 12561743 8 Choriocarcinoma
125617432 12561743 9 Choriocarcinoma
125617432 12561743 10 Product used for unknown indication
125617432 12561743 11 Product used for unknown indication
125617432 12561743 12 Product used for unknown indication

Outcome of event

Event ID CASEID OUTC COD
125617432 12561743 DE

Reactions reported

Event ID CASEID DRUG REC ACT PT
125617432 12561743 Acute lymphocytic leukaemia
125617432 12561743 Choriocarcinoma
125617432 12561743 Invasive ductal breast carcinoma
125617432 12561743 Metastases to central nervous system
125617432 12561743 Treatment failure

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

no results found